Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 15/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 11/20 | 0.61 |
| ▸ | PDE2A | O00408 | 8/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | TSPO | P30536 | 1/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | PTGFR | P43088 | 1/20 | 0.57 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.57 |
| ▸ | PTGIR | P43119 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458417 | 0.84 | PTGDR (0.86) | PTGDRTBXA2RPDE2APDE4ATSPO | |
| SCHEMBL1254325 | 0.83 | PTGDR (0.73) | PTGDRTBXA2RPDE2APTGER1PTGFR | |
| SCHEMBL1255175 | 0.83 | PTGDR (0.73) | PTGDRTBXA2RPDE2APTGER1PTGFR | |
| SCHEMBL7248571 | 0.80 | PDE2A (0.68) | PTGDRTBXA2RPDE2APDE4ATSPO | |
| SCHEMBL9519276 | 0.78 | TBXA2R (0.67) | PTGDRTBXA2RPDE2APTGER1PTGFR | |
| SCHEMBL991121 | 0.76 | PTGDR (1.00) | PTGDRTBXA2RPDE2APDE4ATSPO | |
| SCHEMBL4548354 | 0.76 | PTGDR (1.00) | PTGDRTBXA2RPDE2APDE4ATSPO | |
| SCHEMBL6470520 | 0.76 | PTGDR (0.74) | PTGDRTBXA2RPDE2APDE4ATSPO | |
| SCHEMBL9521310 | 0.73 | TBXA2R (0.64) | PTGDRTBXA2RPDE2A | |
| Diastereomer 2 SCHEMBL1044552 | 0.72 | PTGDR (1.00) | PTGDRTBXA2RPDE2APDE4ATSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | FFAR1, HCAR1, GPR119 | PTGDR 527/4885TBXA2R 68/4885PDE2A 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.